WO2000061597A1 - Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin - Google Patents
Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin Download PDFInfo
- Publication number
- WO2000061597A1 WO2000061597A1 PCT/US2000/009311 US0009311W WO0061597A1 WO 2000061597 A1 WO2000061597 A1 WO 2000061597A1 US 0009311 W US0009311 W US 0009311W WO 0061597 A1 WO0061597 A1 WO 0061597A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligonucleotide
- nucleolin
- oligonucleotides
- binding
- rich
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
- C12N2310/151—Nucleic acids forming more than 2 strands, e.g. TFOs more than 3 strands, e.g. tetrads, H-DNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/958,251 US7314926B1 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin |
JP2000610866A JP2002541264A (en) | 1999-04-08 | 2000-04-07 | Anti-proliferative activity of G-rich oligonucleotide and its use for binding to nucleolin |
DE60036700T DE60036700T2 (en) | 1999-04-08 | 2000-04-07 | ANTIPROLIFERATIVE ACTIVITY OF G-rich OLIGONUCLEOTIDES AND METHOD TO USE THEM TO BIND NUCLEOTINE |
CA002370000A CA2370000A1 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
EP00921868A EP1181304B1 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
AU42129/00A AU775412B2 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
DK00921868T DK1181304T3 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative effect of G-rich oligonucleotides and method of using them to bind nucleolin |
US10/978,032 US8648051B2 (en) | 1999-04-08 | 2004-10-29 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,364 US20110178161A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,427 US7960540B2 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,451 US20080318890A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,413 US8114850B2 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,446 US20080318889A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12831699P | 1999-04-08 | 1999-04-08 | |
US60/128,316 | 1999-04-08 | ||
US14982399P | 1999-08-19 | 1999-08-19 | |
US60/149,823 | 1999-08-19 |
Related Child Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/958,251 A-371-Of-International US7314926B1 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin |
US10/978,032 Division US8648051B2 (en) | 1999-04-08 | 2004-10-29 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,451 Continuation-In-Part US20080318890A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,364 Continuation-In-Part US20110178161A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,446 Continuation-In-Part US20080318889A1 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,427 Continuation-In-Part US7960540B2 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US11/982,413 Continuation-In-Part US8114850B2 (en) | 1999-04-08 | 2007-10-31 | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000061597A1 true WO2000061597A1 (en) | 2000-10-19 |
WO2000061597A9 WO2000061597A9 (en) | 2001-11-29 |
Family
ID=26826478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/009311 WO2000061597A1 (en) | 1999-04-08 | 2000-04-07 | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
Country Status (12)
Country | Link |
---|---|
US (2) | US7314926B1 (en) |
EP (1) | EP1181304B1 (en) |
JP (1) | JP2002541264A (en) |
AT (1) | ATE375358T1 (en) |
AU (1) | AU775412B2 (en) |
CA (1) | CA2370000A1 (en) |
CY (1) | CY1106991T1 (en) |
DE (1) | DE60036700T2 (en) |
DK (1) | DK1181304T3 (en) |
ES (1) | ES2296615T3 (en) |
PT (1) | PT1181304E (en) |
WO (1) | WO2000061597A1 (en) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1492440A2 (en) * | 2002-04-08 | 2005-01-05 | University of Louisville | A new method for the diagnosis and prognosis of malignant diseases |
WO2005035579A1 (en) | 2003-10-09 | 2005-04-21 | University Of Louisville Research Foundation, Inc. | A method for the treatment of maligant diseases by inhibiting nucleolin |
WO2005037323A2 (en) * | 2003-10-10 | 2005-04-28 | University Of Louisville Research Foundation, Inc. | Use of gro to treat or prevent inflammation |
WO2007125210A2 (en) | 2006-04-27 | 2007-11-08 | Centre National De La Recherche Scientifique (Cnrs) | Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation |
WO2009098464A2 (en) * | 2008-02-05 | 2009-08-13 | Antisoma Research Limited | Biological materials and uses thereof |
GB2460086A (en) * | 2008-05-16 | 2009-11-18 | Antisoma Res Ltd | Treatment of paediatric cancers |
WO2011133142A1 (en) * | 2010-04-20 | 2011-10-27 | University Of Louisville | Treatment of vhl-negative tumors |
US8048983B2 (en) * | 2002-04-05 | 2011-11-01 | Sanford-Burnham Medical Research Institute | HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells |
WO2012167173A1 (en) | 2011-06-02 | 2012-12-06 | The University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
US8481529B2 (en) | 2006-05-16 | 2013-07-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Combination cancer chemotherapy |
EP2814498A1 (en) * | 2012-02-16 | 2014-12-24 | University of Toronto | Guanosine-rich oligonucleotide (gro) compositions, methods and uses for treating respiratory syncytial virus infection |
US9243030B2 (en) | 2008-05-22 | 2016-01-26 | Centre National De La Recherche Scientifique (Cnrs) | Optically pure compounds for improved therapeutic efficiency |
EP2982756A1 (en) * | 2014-08-04 | 2016-02-10 | Berlin Cures Holding AG | Aptamers for use against autoantibody-associated diseases |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
US9487559B2 (en) | 2010-10-04 | 2016-11-08 | Elro Pharma Sarl | Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans |
WO2016179394A1 (en) | 2015-05-05 | 2016-11-10 | Malik Mohammad Tariq | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
WO2018026958A1 (en) | 2016-08-02 | 2018-02-08 | The University Of Louisville Research Foundation, Inc. | Targeted nanodroplet emulsions for treating cancer |
JP2019500431A (en) * | 2015-12-23 | 2019-01-10 | クイーンズランド ユニバーシティ オブ テクノロジー | Nucleic acid oligomers and their uses |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1181304B1 (en) * | 1999-04-08 | 2007-10-10 | Antisoma Research Limited | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
US20110178161A1 (en) * | 1999-04-08 | 2011-07-21 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US8114850B2 (en) | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US7960540B2 (en) | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US20090131351A1 (en) * | 2007-11-16 | 2009-05-21 | Antisoma Research Limited | Methods, compositions, and kits for modulating tumor cell proliferation |
US8410070B2 (en) * | 2008-09-12 | 2013-04-02 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death |
KR100998365B1 (en) * | 2009-06-29 | 2010-12-06 | 압타바이오 주식회사 | Novel guanosine rich modified oligonucleotides and antiproliferative activity thereof |
WO2011109677A2 (en) * | 2010-03-04 | 2011-09-09 | University Of Louisville Research Foundation, Inc. | Methods of increasing macropinocytosis in cancer cells |
US20150045248A1 (en) * | 2012-02-28 | 2015-02-12 | National University Corporation Tokyo University Of Agriculture And Technology | Method for identifying disease associated with abundance of tdp-43 in cell |
KR102213609B1 (en) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | Chiral control |
EP3468605A4 (en) | 2016-06-08 | 2020-01-08 | President and Fellows of Harvard College | Engineered viral vector reduces induction of inflammatory and immune responses |
KR20190065139A (en) | 2017-12-01 | 2019-06-11 | 압타바이오 주식회사 | Therapeutics of blood cancer |
EP4163288A1 (en) | 2020-05-19 | 2023-04-12 | Anygen Co., Ltd. | Novel nucleolin-binding peptide and use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5645986A (en) * | 1992-05-13 | 1997-07-08 | Board Of Reagents, The University Of Texas System | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
Family Cites Families (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4141359A (en) | 1976-08-16 | 1979-02-27 | University Of Utah | Epidermal iontophoresis device |
US5705334A (en) | 1988-09-22 | 1998-01-06 | Massachusetts Institute Of Technology | Uses for DNA structure-specific recognition protein |
US5359047A (en) | 1988-09-22 | 1994-10-25 | Massachusetts Institute Of Technology | Nucleic acids encoding DNA structure-specific recognition protein and uses therefor |
US5495070A (en) | 1988-10-04 | 1996-02-27 | Agracetus, Inc. | Genetically engineering cotton plants for altered fiber |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
CA2006008C (en) * | 1988-12-20 | 2000-02-15 | Donald J. Kessler | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5714575A (en) | 1989-02-13 | 1998-02-03 | The University Of Medicine And Dentistry Of New Jersey | Nucleic acids sequence, stress-induced proteins and uses thereof |
US5561222A (en) | 1989-11-15 | 1996-10-01 | Duke University | RNA-binding proteins useful for the control of cellular genetic processing and expression |
US5212058A (en) | 1990-05-09 | 1993-05-18 | Massachusetts Institute Of Technology | Nucleic acid encoding ubiquitin-specific proteases |
DE4021571A1 (en) | 1990-07-06 | 1992-01-16 | Boehringer Mannheim Gmbh | N-METHYLHYDANTOINASE, CLONED |
US5776672A (en) | 1990-09-28 | 1998-07-07 | Kabushiki Kaisha Toshiba | Gene detection method |
US5310892A (en) | 1990-12-10 | 1994-05-10 | The Rockefeller University | Nucleic acid sequence which codes for and expresses human fibrillarin and uses thereof |
US5470971A (en) | 1991-03-11 | 1995-11-28 | The University Of Medicine And Dentistry Of New Jersey | Stress-induced proteins, genes coding therefor, transformed cells of organisms, methods and applications |
US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
US5925729A (en) | 1991-05-23 | 1999-07-20 | Ludwig Institute For Cancer Research | Tumor rejection antigen precursors, tumor rejection antigens and uses thereof |
US5612201A (en) | 1991-05-23 | 1997-03-18 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
US5624818A (en) | 1991-09-09 | 1997-04-29 | Fred Hutchinson Cancer Research Center | Nucleic acids encoding regulatory proteins that dimerize with Mad or Max |
US5262409A (en) | 1991-10-11 | 1993-11-16 | Fred Hutchinson Cancer Research Center | Binary tumor therapy |
US5376546A (en) | 1991-11-04 | 1994-12-27 | Xoma Corporation | Analogs of ribosome-inactivating proteins |
US5688511A (en) | 1991-11-05 | 1997-11-18 | Board Of Regents, The University Of Texas System | Cellular protein TDP-43 and regulation of HIV-1 gene expression |
US6153408A (en) | 1991-11-15 | 2000-11-28 | Institut Pasteur And Institut National De La Sante Et De La Recherche Medicale | Altered major histocompatibility complex (MHC) determinant and methods of using the determinant |
US5499967A (en) | 1992-02-27 | 1996-03-19 | Societe Anonyme Dite: Laboratoires D'hygiene Societe Anonyme Dite: Et De Dietetique (L.H.D.) | Transdermal drug delivery device with waveshape generator |
US6036955A (en) | 1992-03-05 | 2000-03-14 | The Scripps Research Institute | Kits and methods for the specific coagulation of vasculature |
US6093399A (en) | 1992-03-05 | 2000-07-25 | Board Of Regents, The University Of Texas System | Methods and compositions for the specific coagulation of vasculature |
US6235313B1 (en) | 1992-04-24 | 2001-05-22 | Brown University Research Foundation | Bioadhesive microspheres and their use as drug delivery and imaging systems |
US5444149A (en) | 1992-05-11 | 1995-08-22 | Duke University | Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation |
US5686306A (en) | 1992-05-13 | 1997-11-11 | Board Of Regents, The University Of Texas System | Methods and reagents for lengthening telomeres |
US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
US5523389A (en) | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
US5834247A (en) | 1992-12-09 | 1998-11-10 | New England Biolabs, Inc. | Modified proteins comprising controllable intervening protein sequences or their elements methods of producing same and methods for purification of a target protein comprised by a modified protein |
US6288042B1 (en) | 1993-04-23 | 2001-09-11 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich tetrad forming oligonucleotides |
US5567604A (en) * | 1993-04-23 | 1996-10-22 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
US6323185B1 (en) | 1993-04-23 | 2001-11-27 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-viral guanosine-rich oligonucleotides and method of treating HIV |
US5443962A (en) | 1993-06-04 | 1995-08-22 | Mitotix, Inc. | Methods of identifying inhibitors of cdc25 phosphatase |
US6479055B1 (en) | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
US6017536A (en) | 1993-06-07 | 2000-01-25 | Trimeris, Inc. | Simian immunodeficiency virus peptides with antifusogenic and antiviral activities |
US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
US5614503A (en) | 1993-11-12 | 1997-03-25 | Aronex Pharmaceuticals, Inc. | Amphipathic nucleic acid transporter |
US5804380A (en) | 1993-11-12 | 1998-09-08 | Geron Corporation | Telomerase activity assays |
US5449758A (en) | 1993-12-02 | 1995-09-12 | Life Technologies, Inc. | Protein size marker ladder |
US5625031A (en) | 1994-02-08 | 1997-04-29 | Bristol-Myers Squibb Company | Peptide inhibitors of the p33cdk2 and p34cdc2 cell cycle regulatory kinases and human papillomavirus E7 oncoprotein |
US5763174A (en) | 1994-02-17 | 1998-06-09 | The Wistar Institute Of Anatomy & Biology | RNA editing enzyme and methods of use thereof |
US5643778A (en) | 1994-02-17 | 1997-07-01 | The Wistar Institute Of Anatomy & Biology | RNA editing enzyme and methods of use thereof |
US5594120A (en) | 1994-02-18 | 1997-01-14 | Brigham And Women's Hospital, Inc. | Integrin alpha subunit |
US6037329A (en) | 1994-03-15 | 2000-03-14 | Selective Genetics, Inc. | Compositions containing nucleic acids and ligands for therapeutic treatment |
US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
US6183751B1 (en) | 1994-08-18 | 2001-02-06 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's Sarcoma virus sequences and uses thereof |
US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
US5631146A (en) | 1995-01-19 | 1997-05-20 | The General Hospital Corporation | DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
US5643890A (en) | 1995-01-31 | 1997-07-01 | The Board Of Regents Of The University Of Nebraska | Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases |
DE19502912A1 (en) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilized Oligonucleotides |
US5932556A (en) | 1995-09-17 | 1999-08-03 | Tam; Robert C | Methods and compositions for regulation of CD28 expression |
US5624799A (en) | 1995-02-13 | 1997-04-29 | The Burnham Institute | Cancer-associated mar binding protein |
US6020139A (en) | 1995-04-25 | 2000-02-01 | Oridigm Corporation | S-adenosyl methionine regulation of metabolic pathways and its use in diagnosis and therapy |
WO1996035126A1 (en) | 1995-05-03 | 1996-11-07 | President And Fellows Of Harvard College | Assessing calcineurin's role in immunosuppression and neurotoxicity |
US5843732A (en) | 1995-06-06 | 1998-12-01 | Nexstar Pharmaceuticals, Inc. | Method and apparatus for determining consensus secondary structures for nucleic acid sequences |
US5763178A (en) | 1995-06-07 | 1998-06-09 | Trevigen, Inc. | Oscillating signal amplifier for nucleic acid detection |
US5741677A (en) | 1995-06-07 | 1998-04-21 | Geron Corporation | Methods for measuring telomere length |
US5656430A (en) | 1995-06-07 | 1997-08-12 | Trevigen, Inc. | Oscillating signal amplifier for nucleic acid detection |
US6054442A (en) | 1995-07-06 | 2000-04-25 | Board Of Regents, University Of Texas System | Methods and compositions for modulation and inhibition of telomerase in vitro |
US5968506A (en) | 1995-08-04 | 1999-10-19 | Geron Corporation | Purified telomerase |
US5776696A (en) | 1995-09-15 | 1998-07-07 | Merck & Co., Inc. | High throughput assay using fusion proteins |
US5783398A (en) | 1995-09-15 | 1998-07-21 | Merck & Co., Inc. | High throughput assay using fusion proteins |
US5854223A (en) | 1995-10-06 | 1998-12-29 | The Trustees Of Columbia University In The City Of New York | S-DC28 as an antirestenosis agent after balloon injury |
US5861498A (en) | 1995-11-01 | 1999-01-19 | Thomas Jefferson University | Nucleotides encoding immunophilin FKBP46 and fragments thereof |
JP3089350B2 (en) | 1995-11-20 | 2000-09-18 | ギルフォード ファーマシューティカルズ インコーポレイテッド | Inhibitors of cyclophilin rotamase activity |
US6214805B1 (en) | 1996-02-15 | 2001-04-10 | The United States Of America As Represented By The Department Of Health And Human Services | RNase L activators and antisense oligonucleotides effective to treat RSV infections |
US5985320A (en) | 1996-03-04 | 1999-11-16 | The Penn State Research Foundation | Materials and methods for enhancing cellular internalization |
US6274313B1 (en) | 1996-03-21 | 2001-08-14 | Pioneer-Hybrid International, Inc. | Oligonucleotides with cationic phosphoramidate internucleoside linkages and methods of use |
US6331617B1 (en) | 1996-03-21 | 2001-12-18 | University Of Iowa Research Foundation | Positively charged oligonucleotides as regulators of gene expression |
US5734040A (en) | 1996-03-21 | 1998-03-31 | University Of Iowa Research Foundation | Positively charged oligonucleotides as regulators of gene expression |
US6030955A (en) | 1996-03-21 | 2000-02-29 | The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. | Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof |
AU2542097A (en) | 1996-03-26 | 1997-10-17 | Lynx Therapeutics, Inc. | Oligonucleotide treatments and compositions for human melanoma |
CA2175435A1 (en) | 1996-04-30 | 1997-10-31 | Joseph Lam | Proteins involved in the synthesis and assembly of o-antigen in pseudomonas aeruginosa |
US6027881A (en) | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
US5756710A (en) | 1996-06-05 | 1998-05-26 | The Trustees Of Columbia University In City Of New York | Phosphorothioate oligonucleotides that bind to the V3-loop and uses thereof |
US5792613A (en) | 1996-06-12 | 1998-08-11 | The Curators Of The University Of Missouri | Method for obtaining RNA aptamers based on shape selection |
US5780447A (en) | 1996-06-14 | 1998-07-14 | St. Jude Children's Research Hospital | Recombinant adeno-associated viral vectors |
US6348586B1 (en) | 1996-07-25 | 2002-02-19 | The Trustees Of Columbia University In The City Of New York | Unique associated Kaposi's sarcoma virus sequences and uses thereof |
US6107029A (en) | 1996-07-31 | 2000-08-22 | Message Pharmaceticals, Inc. | Universal method for detecting interactions between RNA molecules and RNA binding proteins |
US5691145A (en) | 1996-08-27 | 1997-11-25 | Becton, Dickinson And Company | Detection of nucleic acids using G-quartets |
US5898860A (en) * | 1996-10-01 | 1999-04-27 | Leibold; William Steven | System and method for automatically generating a control drawing for a real-time process control system |
US6475789B1 (en) | 1996-10-01 | 2002-11-05 | University Technology Corporation | Human telomerase catalytic subunit: diagnostic and therapeutic methods |
KR20000048820A (en) | 1996-10-01 | 2000-07-25 | 게론 코포레이션 | Telomerase reverse transcriptase |
US5849564A (en) | 1996-11-29 | 1998-12-15 | The Trustees Of Columbia University In The City Of New York | Polypeptides from Kaposi's sarcoma-associated herpesvirus, DNA encoding same and uses thereof |
WO1998029736A1 (en) | 1996-12-31 | 1998-07-09 | Genometrix Incorporated | Multiplexed molecular analysis apparatus and method |
US6416959B1 (en) | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
FR2763943B1 (en) | 1997-05-28 | 1999-07-09 | Rhone Poulenc Rorer Sa | COMPOUNDS, THEIR PREPARATION AND THEIR USE FOR TRANSFERRING NUCLEIC ACIDS INTO CELLS |
US6028058A (en) | 1997-07-21 | 2000-02-22 | Ciblex Corporation | Methods and compositions for regulating nuclear trafficking of proteins |
AU750947C (en) | 1997-09-22 | 2003-05-22 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Nucleic acid catalysts with endonuclease activity |
US6025194A (en) | 1997-11-19 | 2000-02-15 | Geron Corporation | Nucleic acid sequence of senescence asssociated gene |
US6455250B1 (en) | 1997-12-11 | 2002-09-24 | The Regents Of The University Of California | Endonuclease compositions and methods of use |
US5932475A (en) | 1997-12-12 | 1999-08-03 | Incyte Pharmaceuticals, Inc. | Human nucleolin-like protein |
US5989860A (en) | 1997-12-12 | 1999-11-23 | Incyte Pharmaceuticals, Inc. | Human isomerase homologs |
US5989823A (en) | 1998-09-18 | 1999-11-23 | Nexstar Pharmaceuticals, Inc. | Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction |
US6376226B1 (en) | 1998-01-09 | 2002-04-23 | Thomas Jefferson University | Recombinant, active caspases and uses thereof |
US6071732A (en) | 1998-01-29 | 2000-06-06 | The Board Of Regents Of The University Of Oklahoma | Tyrosylprotein sulfotransferases, nucleic acids encoding tyrosylprotein sulfotransferases, and methods of use thereof |
US6255055B1 (en) | 1998-03-09 | 2001-07-03 | Wisconsin Alumni Research Foundation | c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence |
US6332897B1 (en) | 1998-03-27 | 2001-12-25 | Glaxo Wellcome Inc. | Assay methods |
US6180348B1 (en) | 1998-04-20 | 2001-01-30 | Weihua Li | Method of isolating target specific oligonucleotide ligands |
US6017709A (en) | 1998-04-29 | 2000-01-25 | University Of Houston | DNA replication templates stabilized by guanine quartets |
US6171843B1 (en) | 1998-06-01 | 2001-01-09 | Incyte Pharmaceuticals, Inc. | Human peptidyl-prolyl isomerases |
US6274725B1 (en) | 1998-06-02 | 2001-08-14 | Isis Pharmaceuticals, Inc. | Activators for oligonucleotide synthesis |
JP4013333B2 (en) * | 1998-06-05 | 2007-11-28 | 株式会社B&Cラボラトリーズ | Method for measuring skin aging and measuring kit |
AU5492499A (en) | 1998-08-21 | 2000-03-14 | University Of Virginia Patent Foundation | Signal generating oligonucleotide-based biosensor |
EP1115737A4 (en) | 1998-09-23 | 2004-11-24 | Cleveland Clinic Foundation | Novel interferon stimulated and repressed genes |
US6465176B1 (en) | 1998-10-02 | 2002-10-15 | Message Pharmaceuticals, Inc. | Method for identifying compounds RNA/RNA binding protein interactions |
US6423493B1 (en) | 1998-10-26 | 2002-07-23 | Board Of Regents The University Of Texas System | Combinatorial selection of oligonucleotide aptamers |
US6426231B1 (en) | 1998-11-18 | 2002-07-30 | The Texas A&M University System | Analyte sensing mediated by adapter/carrier molecules |
US6177254B1 (en) | 1998-12-15 | 2001-01-23 | Jerome Bernard Rattner | Nucleolus autoantigenic marker for systemic lupus erthyematosus |
US5948680A (en) | 1998-12-17 | 1999-09-07 | Isis Pharmaceuticals Inc. | Antisense inhibition of Elk-1 expression |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
ES2333399T3 (en) | 1999-03-29 | 2010-02-22 | Shire Canada Inc. | METHODS TO TREAT A LEUKEMIA. |
US6383752B1 (en) | 1999-03-31 | 2002-05-07 | Hybridon, Inc. | Pseudo-cyclic oligonucleobases |
US20080318890A1 (en) | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
EP1181304B1 (en) | 1999-04-08 | 2007-10-10 | Antisoma Research Limited | Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
US8114850B2 (en) | 1999-04-08 | 2012-02-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US20080318889A1 (en) | 1999-04-08 | 2008-12-25 | Antisoma Research Limited | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
US7960540B2 (en) | 1999-04-08 | 2011-06-14 | Advanced Cancer Therapeutics, Llc | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
DE60001531T2 (en) | 1999-04-23 | 2003-10-02 | Molecular Probes Inc | XANTHENE DYES AND THEIR USE AS LUMINESCENT EXTINGUISHING COMPOUNDS |
US6316200B1 (en) | 2000-06-08 | 2001-11-13 | Becton, Dickinson And Company | Probes and methods for detection of nucleic acids |
US6200746B1 (en) | 1999-08-25 | 2001-03-13 | Pharmacia & Upjohn Company | Methods of identifying anti-viral agents |
US6379888B1 (en) | 1999-09-27 | 2002-04-30 | Becton, Dickinson And Company | Universal probes and methods for detection of nucleic acids |
US6420122B1 (en) | 1999-09-27 | 2002-07-16 | Massachusetts Institute Of Technology | Methods of screening for agents that inhibit aggregation of polypeptides |
US6165789A (en) | 1999-10-27 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of hnRNP A1 expression |
US6165786A (en) | 1999-11-03 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Antisense modulation of nucleolin expression |
CA2393808A1 (en) | 1999-12-13 | 2001-06-21 | Bioniche Life Sciences Inc. | Anti-cancer synthetic oligonucleotides |
US6291187B1 (en) | 2000-05-12 | 2001-09-18 | Molecular Staging, Inc. | Poly-primed amplification of nucleic acid sequences |
US7541150B2 (en) | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
WO2004003554A1 (en) | 2002-06-26 | 2004-01-08 | University Of Louisville Research Foundation, Inc. | A method for the detection of apoptosis |
US20050187176A1 (en) | 2003-10-10 | 2005-08-25 | Bates Paula J. | Method for inhibiting NF-kappa B signaling and use to treat or prevent human diseases |
US20090131351A1 (en) | 2007-11-16 | 2009-05-21 | Antisoma Research Limited | Methods, compositions, and kits for modulating tumor cell proliferation |
EP2268284A2 (en) | 2008-02-05 | 2011-01-05 | Antisoma Research Limited | Use of g-rich oligonucleotides for treating neoplastic diseases |
-
2000
- 2000-04-07 EP EP00921868A patent/EP1181304B1/en not_active Expired - Lifetime
- 2000-04-07 DK DK00921868T patent/DK1181304T3/en active
- 2000-04-07 AT AT00921868T patent/ATE375358T1/en not_active IP Right Cessation
- 2000-04-07 AU AU42129/00A patent/AU775412B2/en not_active Ceased
- 2000-04-07 CA CA002370000A patent/CA2370000A1/en not_active Abandoned
- 2000-04-07 DE DE60036700T patent/DE60036700T2/en not_active Expired - Lifetime
- 2000-04-07 JP JP2000610866A patent/JP2002541264A/en not_active Ceased
- 2000-04-07 PT PT00921868T patent/PT1181304E/en unknown
- 2000-04-07 US US09/958,251 patent/US7314926B1/en not_active Expired - Lifetime
- 2000-04-07 ES ES00921868T patent/ES2296615T3/en not_active Expired - Lifetime
- 2000-04-07 WO PCT/US2000/009311 patent/WO2000061597A1/en active IP Right Grant
-
2004
- 2004-10-29 US US10/978,032 patent/US8648051B2/en not_active Expired - Lifetime
-
2007
- 2007-11-08 CY CY20071101441T patent/CY1106991T1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5645986A (en) * | 1992-05-13 | 1997-07-08 | Board Of Reagents, The University Of Texas System | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
Non-Patent Citations (2)
Title |
---|
BATES. ET. AL.: "Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 37, 10 September 1999 (1999-09-10), pages 26369 - 26377, XP002928374 * |
MATA ET. AL.: "A Hexameric Phosphorothioate Oligonucleotide Telomerase Inhibitor Arrests Growth of Burkitt's Lymphoma Cells in Vitro or in Vivo", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 144, 1997, pages 189 - 197, XP002913088 * |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8048983B2 (en) * | 2002-04-05 | 2011-11-01 | Sanford-Burnham Medical Research Institute | HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells |
US8598112B2 (en) | 2002-04-05 | 2013-12-03 | Erkki Ruoslahti | HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells |
US20120121501A1 (en) * | 2002-04-05 | 2012-05-17 | Sanford-Burnham Medical Research Institute | Hmgn2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells |
JP4841109B2 (en) * | 2002-04-08 | 2011-12-21 | ユニヴァーシティ オブ ルイスヴィル リサーチ ファウンデイション インコーポレイテッド | Diagnosis and prediction method for malignant diseases |
US8029784B2 (en) | 2002-04-08 | 2011-10-04 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
JP2005526968A (en) * | 2002-04-08 | 2005-09-08 | ユニヴァーシティ オブ ルイスヴィル リサーチ ファウンデイション インコーポレイテッド | Diagnosis and prediction method for malignant diseases |
JP2011246467A (en) * | 2002-04-08 | 2011-12-08 | Univ Of Louisville Research Foundation Inc | Method for diagnosis and prognosis of malignant disease |
US7541150B2 (en) | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
EP1492440A2 (en) * | 2002-04-08 | 2005-01-05 | University of Louisville | A new method for the diagnosis and prognosis of malignant diseases |
US8586717B2 (en) | 2002-04-08 | 2013-11-19 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
EP1492440A4 (en) * | 2002-04-08 | 2005-08-24 | Univ Louisville Res Found | A new method for the diagnosis and prognosis of malignant diseases |
WO2005035579A1 (en) | 2003-10-09 | 2005-04-21 | University Of Louisville Research Foundation, Inc. | A method for the treatment of maligant diseases by inhibiting nucleolin |
WO2005037323A3 (en) * | 2003-10-10 | 2005-08-18 | Univ Louisville Res Found | Use of gro to treat or prevent inflammation |
WO2005037323A2 (en) * | 2003-10-10 | 2005-04-28 | University Of Louisville Research Foundation, Inc. | Use of gro to treat or prevent inflammation |
US9254309B2 (en) | 2006-04-27 | 2016-02-09 | Centre National De La Recherche Scientifique (Cnrs) | Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation |
US8497349B2 (en) | 2006-04-27 | 2013-07-30 | Centre National De La Recherche Scientifique (Cnrs) | Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation |
WO2007125210A2 (en) | 2006-04-27 | 2007-11-08 | Centre National De La Recherche Scientifique (Cnrs) | Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation |
US8481529B2 (en) | 2006-05-16 | 2013-07-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Combination cancer chemotherapy |
WO2009098464A3 (en) * | 2008-02-05 | 2010-01-14 | Antisoma Research Limited | Use of g-rich oligonucleotides for treating neoplastic diseases |
WO2009098464A2 (en) * | 2008-02-05 | 2009-08-13 | Antisoma Research Limited | Biological materials and uses thereof |
GB2460086A (en) * | 2008-05-16 | 2009-11-18 | Antisoma Res Ltd | Treatment of paediatric cancers |
US9243030B2 (en) | 2008-05-22 | 2016-01-26 | Centre National De La Recherche Scientifique (Cnrs) | Optically pure compounds for improved therapeutic efficiency |
US10385128B2 (en) | 2009-11-17 | 2019-08-20 | Musc Foundation For Research Development | Nucleolin antibodies |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
WO2011133142A1 (en) * | 2010-04-20 | 2011-10-27 | University Of Louisville | Treatment of vhl-negative tumors |
US9487559B2 (en) | 2010-10-04 | 2016-11-08 | Elro Pharma Sarl | Compositions comprising multivalent synthetic ligands of surface nucleolin and glycosaminoglycans |
US11344633B2 (en) | 2011-06-02 | 2022-05-31 | University Of Louisville Research Foundation, Inc | Anti-nucleolin agent-conjugated nanoparticles |
WO2012167173A1 (en) | 2011-06-02 | 2012-12-06 | The University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
EP3446714A1 (en) | 2011-06-02 | 2019-02-27 | University of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
EP3011974A1 (en) | 2011-06-02 | 2016-04-27 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
US9452219B2 (en) | 2011-06-02 | 2016-09-27 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
EP2814498A4 (en) * | 2012-02-16 | 2015-02-25 | Univ Toronto | Guanosine-rich oligonucleotide (gro) compositions, methods and uses for treating respiratory syncytial virus infection |
US9476049B2 (en) | 2012-02-16 | 2016-10-25 | The Governing Council Of The University Of Toronto | Guanosine-rich oligonucleotide (GRO) compositions, methods and uses for treating respiratory syncytial virus infection |
EP2814498A1 (en) * | 2012-02-16 | 2014-12-24 | University of Toronto | Guanosine-rich oligonucleotide (gro) compositions, methods and uses for treating respiratory syncytial virus infection |
EP2982756A1 (en) * | 2014-08-04 | 2016-02-10 | Berlin Cures Holding AG | Aptamers for use against autoantibody-associated diseases |
JP2018171070A (en) * | 2014-08-04 | 2018-11-08 | ベルリン キュアーズ ホールディング アクチェンゲゼルシャフト | Aptamers for use against autoantibody associated diseases |
JP2017529872A (en) * | 2014-08-04 | 2017-10-12 | ベルリン キュアーズ ホールディング アクチェンゲゼルシャフト | Aptamers for use against autoantibody-related diseases |
WO2016020377A1 (en) * | 2014-08-04 | 2016-02-11 | Berlin Cures Holding Ag | Aptamers for use against autoantibody-associated diseases |
CN106795516A (en) * | 2014-08-04 | 2017-05-31 | 柏林制药控股公司 | For the fit of auto-antibody relevant disease |
JP2021035369A (en) * | 2014-08-04 | 2021-03-04 | ベルリン キュアーズ ホールディング アクチェンゲゼルシャフト | Aptamers for use against autoantibody-associated diseases |
US10857237B2 (en) | 2015-05-05 | 2020-12-08 | University Of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents |
WO2016179394A1 (en) | 2015-05-05 | 2016-11-10 | Malik Mohammad Tariq | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
JP2019500431A (en) * | 2015-12-23 | 2019-01-10 | クイーンズランド ユニバーシティ オブ テクノロジー | Nucleic acid oligomers and their uses |
EP3393480A4 (en) * | 2015-12-23 | 2020-04-22 | Queensland University Of Technology | Nucleic acid oligomers and uses therefor |
JP2022088371A (en) * | 2015-12-23 | 2022-06-14 | シーエーアールピー ファーマシューティカルズ プロプライアタリー リミティド | Nucleic acid oligomer and application of the same |
US11534451B2 (en) | 2015-12-23 | 2022-12-27 | Repluca Pty Ltd | Nucleic acid oligomers and uses therefor |
US11911410B2 (en) | 2015-12-23 | 2024-02-27 | Repluca Pty Ltd | Nucleic acid oligomers and uses therefor |
WO2018026958A1 (en) | 2016-08-02 | 2018-02-08 | The University Of Louisville Research Foundation, Inc. | Targeted nanodroplet emulsions for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
ATE375358T1 (en) | 2007-10-15 |
DK1181304T3 (en) | 2008-02-11 |
WO2000061597A9 (en) | 2001-11-29 |
CA2370000A1 (en) | 2000-10-19 |
ES2296615T3 (en) | 2008-05-01 |
EP1181304B1 (en) | 2007-10-10 |
US20090326047A1 (en) | 2009-12-31 |
PT1181304E (en) | 2008-01-23 |
AU775412B2 (en) | 2004-07-29 |
US7314926B1 (en) | 2008-01-01 |
US8648051B2 (en) | 2014-02-11 |
CY1106991T1 (en) | 2012-09-26 |
JP2002541264A (en) | 2002-12-03 |
DE60036700T2 (en) | 2008-07-24 |
AU4212900A (en) | 2000-11-14 |
EP1181304A4 (en) | 2002-10-02 |
DE60036700D1 (en) | 2007-11-22 |
EP1181304A1 (en) | 2002-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7314926B1 (en) | Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin | |
Crooke | Antisense therapeutics | |
US6369038B1 (en) | Closed antisense and sense oligonucleotides and their applications | |
Agrawal | Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides | |
JP3054745B2 (en) | Antisense oligonucleotide regulation of raf gene expression | |
EP2364990A1 (en) | Modulators of pharmacological agents | |
US20020039741A1 (en) | Antisense oligonucleotide compositions and methods for the modulation of activating protein 1 | |
Ma et al. | Synthetic oligonucleotides as therapeutics: the coming of age | |
US8114850B2 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin | |
US6001991A (en) | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression | |
US7960540B2 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin | |
Jing et al. | Rational drug design of G-quartet DNA as anti-cancer agents | |
US20080318890A1 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin | |
US20080318889A1 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin | |
EP1432450B1 (en) | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides | |
EP1930340A1 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using the same to bind to nucleolin | |
US20110178161A1 (en) | Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin | |
Stein et al. | Antisense oligodeoxynucleotides: Internalization, compartmentalization and non-sequence specificity | |
AU2002341264A1 (en) | Therapeutically useful triethyleneglycol cholesteryl oligonucleotides | |
CA2743828C (en) | Fas/fasl or other death receptor targeted methods and compositions for killing tumor cells | |
Geiger et al. | antisense oligonucleotides, mdm2, p53, apoptosis | |
Ziegler et al. | [33] Optimizing efficacy of antisense oligodeoxynucleotides targeting inhibitors of apoptosis | |
US20040142896A1 (en) | High efficacy antisense RIalpha PKA poly-DNP oligoribonucleotides | |
WO2023192828A2 (en) | Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases | |
Tidd et al. | Mechanisms of action of antisense oligonucleotides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2370000 Country of ref document: CA Ref country code: CA Ref document number: 2370000 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 610866 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000921868 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AU CA JP US US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/14-14/14, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09958251 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2000921868 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000921868 Country of ref document: EP |